Efarindodekin Alfa

N/A

Report date: 2025/12/12 17:41:43

Base Information

Drug NameEfarindodekin Alfa
Drug Alias NameXTX-301
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-12 replacements
TargetsInterleukin-12
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesXilio Development Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A